WHO II non-typical brain tumour is a dubious disease in the field of blood tumours, with complex clinical outcomes and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory tests and pathological activation.
The platform can help align national and international experts with teams to provide accurate diagnosis and treatment regimens. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the non-typical comprehensive management of brain tumors of WHO Level II. 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.